Surbhi Singhal, MD

The final segment of the program addresses the practical realities and future outlook of genomic testing in lung cancer.

This segment focuses on one of the most challenging and clinically important aspects of precision oncology in lung cancer, which is how to manage situations when tissue based and liquid biopsy results do not align.

Here the experts discuss how next generation sequencing is transforming lung cancer testing workflows, particularly in community settings.

This segment focuses on how ctDNA and an expanding set of molecular biomarkers are shaping modern lung cancer care.

This section explores how liquid biopsy is used beyond diagnosis to monitor treatment response and disease evolution in lung cancer.

This segment shifts the discussion from theory to real world clinical application by focusing on how genomic profiling directly changes treatment decisions in lung cancer.

This segment examines how comprehensive genomic profiling is now being used earlier in the lung cancer disease course.

This segment focuses on how clinicians decide between tissue biopsy and blood based testing when planning initial genomic evaluation. Dr Singhal describes how patient factors such as tumor location, disease burden, and the feasibility of obtaining a tissue sample guide this decision.

This segment focuses on how clinicians decide between tissue biopsy and blood based testing when planning initial genomic evaluation.

This opening segment introduces the goals of the OncLive Insights program and frames genomic testing as a core element of the modern lung cancer diagnostic pathway.